Leerink Partnrs Comments on Q32 Bio FY2029 Earnings

Q32 Bio Inc. (NASDAQ:QTTB) – Stock analysts at Leerink Partnrs issued their FY2029 earnings estimates for Q32 Bio in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($0.75) for the year. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.32) per share.

Several other brokerages also recently issued reports on QTTB. Oppenheimer lowered their price target on Q32 Bio from $80.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. BMO Capital Markets cut their price target on shares of Q32 Bio from $64.00 to $22.00 and set an “outperform” rating on the stock in a research note on Thursday, December 12th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $16.00 price target (down previously from $95.00) on shares of Q32 Bio in a report on Wednesday, December 11th. Leerink Partners restated a “market perform” rating and set a $9.00 price objective (down from $68.00) on shares of Q32 Bio in a report on Wednesday, December 11th. Finally, Piper Sandler reduced their target price on shares of Q32 Bio from $85.00 to $20.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $29.86.

Q32 Bio Price Performance

QTTB opened at $3.16 on Friday. The company has a fifty day simple moving average of $6.86 and a 200 day simple moving average of $29.27. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.61. The stock has a market cap of $38.49 million, a P/E ratio of -0.22 and a beta of -0.32. Q32 Bio has a 12 month low of $2.90 and a 12 month high of $53.79.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Values First Advisors Inc. bought a new position in shares of Q32 Bio in the third quarter valued at $33,000. Hussman Strategic Advisors Inc. acquired a new stake in Q32 Bio in the fourth quarter valued at $36,000. Raymond James Financial Inc. bought a new position in shares of Q32 Bio in the 4th quarter valued at about $37,000. Drive Wealth Management LLC acquired a new position in shares of Q32 Bio during the 4th quarter worth about $38,000. Finally, Savant Capital LLC bought a new stake in shares of Q32 Bio in the 4th quarter valued at about $53,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.